Status:
COMPLETED
Open-label Study of Curcumin C-3 Complex in Schizophrenia
Lead Sponsor:
Woodbury, Michel, M.D.
Collaborating Sponsors:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
Current evidence suggests that schizophrenia as a serious and complex psychiatric disorder, continues to challenge mental health professionals in their search for better treatment options in the commu...
Detailed Description
Detailed Description: The overall objective of the study was to evaluate whether the standardized proprietary formulation of curcumin \[Super Curcumin@ :C-3 Complex@ with Bioperine@) manufactured by A...
Eligibility Criteria
Inclusion
- Male or female:
- DSMIV (Diagnostic Statistical Manual -TR version) Schizophrenia
- Male or Female ,
- age 18-65 yrs
- SANS (Scale of Negative Symptoms of Schizophrenia ) \> 30
- Stable antipsychotic dosage at least 1 month
Exclusion
- Current Substance use Disorder except Nicotine dependence
- Regular Use of NSAID (non-steroidal anti-inflammatory drugs)
- cancer History
- Recent myocardial infarction
- Unstable angina,
- untreated or severe hypertension
- Poorly controlled diabetes mellitus Type I or Type II
- Chronic liver \& gallbladder diseases
- Recent GERD (Gastroesophageal Reflux Disorder)
- Pregnancy and breast-fed.
- Allergic reaction to Curcumin
- Neurological disorders: epilepsy, stroke
- Hamilton Depression Scale Hamilton Depression Rating Scale( HAM-D-17 item) \> 24 -
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2012
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT01875822
Start Date
June 1 2009
End Date
May 1 2012
Last Update
June 12 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. Michel Woodbury-Farina
San Juan, Puerto Rico, 00918